How to Help Your Patients Find Lubiprostone in Stock: A Provider's Guide

Patients on Lubiprostone (Amitiza) are increasingly showing up at appointments or calling your office because they can't fill their prescription. While there is no official FDA shortage as of 2026, localized stock challenges, generic supply variability, and insurance hurdles are creating real access problems. This guide gives you the practical tools and strategies to help your patients stay on therapy and manage medication access effectively.

Understanding the Landscape: Why Your Patients Are Struggling

For providers who haven't encountered this issue yet, here's a quick overview: Amitiza's patents expired in 2024–2025, triggering a transition to generic Lubiprostone. However, the generic market currently has only a small number of manufacturers. This creates fragile supply dynamics — any manufacturing hiccup or demand spike can cause localized shortfalls. Chain pharmacies also stock based on local demand volumes, so patients in lower-prescription-density areas may find their pharmacy simply doesn't carry it routinely.

Prescribing Strategies That Improve Access

1. Prescribe Generic by Name

Unless there is a clinical reason to specify brand Amitiza, write the prescription for generic Lubiprostone. This increases the number of pharmacies that can fill it (not all carry the brand anymore), and often reduces your patient's out-of-pocket cost from $400–$530 to $60–$150 per month for a 30-day supply at cash prices.

2. Write 90-Day Supplies When Clinically Appropriate

A 90-day supply prescription reduces the frequency with which patients need to search for the medication. When a patient does find a pharmacy with adequate stock, they can fill a full quarter's supply. Many insurers and mail-order pharmacies support 90-day fills, often at a lower per-dose cost. Verify that your patient's plan permits this before writing the prescription.

3. Direct Patients to Independent Pharmacies

When chain pharmacies are out of stock, independent pharmacies are often the better option. They typically work with multiple wholesalers and can source medications that chain distribution centers are short on. If your practice has a relationship with local independent pharmacies, a warm referral from your office can help expedite ordering. Consider keeping a short list of reliable independent pharmacies in your patient care area.

4. Encourage Mail-Order Pharmacy Enrollment

For stable, long-term patients on Lubiprostone, mail-order pharmacy enrollment is one of the most effective ways to avoid stock disruptions. Mail-order pharmacies maintain larger inventory buffers than retail locations and routinely ship 90-day supplies. Many insurance plans offer lower copays for mail-order, which adds a financial incentive. Help your front desk or care coordinators facilitate mail-order enrollment for appropriate patients.

5. Pre-Authorize Early to Avoid Delays

Most commercial and Medicaid plans require prior authorization (PA) for Lubiprostone. Common PA requirements include documented failure of at least one OTC agent (e.g., polyethylene glycol), and for IBS-C, confirmation of female sex (≥18 years). For OIC, documentation of the chronic non-cancer pain indication and current opioid regimen is needed. Build documentation of these clinical elements into your initial visit notes to enable faster PA submission when prescribing.

Patient-Facing Tools Your Office Can Recommend

When patients call reporting they can't find their medication, give your care team a script to recommend medfinder — a service that calls pharmacies near the patient to find which ones have Lubiprostone in stock. Patients provide their medication, dose, and zip code, and medfinder does the pharmacy calling for them. Results are delivered by text. Providers can also use medfinder for providers to check availability at the point of prescribing.

When to Consider a Clinical Switch

If a patient faces a sustained access problem (more than 2 weeks without medication) and all sourcing options have been explored, consider a planned therapeutic switch to an alternative agent. Factors to guide your choice:

• For CIC: Linzess (linaclotide 145 mcg QD) or Trulance (plecanatide 3 mg QD) are first-line equivalents. Motegrity (prucalopride 2 mg QD) is appropriate if secretagogues have previously been ineffective.
• For IBS-C: Linzess (linaclotide 290 mcg QD) or Trulance (plecanatide 3 mg QD) are preferred; they address abdominal pain in addition to constipation. Tenapanor (Ibsrela) is an option for patients who haven't responded to GC-C agonists.
• For OIC: PAMORAs (naloxegol/Movantik, naldemedine/Symproic) specifically target opioid-induced gut dysmotility and are preferred over general secretagogues for this indication.

Savings and Assistance Programs for Your Patients

If patients are struggling financially as well as with supply, direct them to:

• Mallinckrodt Patient Assistance Program: Eligible uninsured patients may receive Amitiza at no cost.
• GoodRx / SingleCare discount cards: Generic Lubiprostone available for $33–$50 with discount cards at participating pharmacies.
• NeedyMeds.org and RxAssist.org: Comprehensive databases of patient assistance programs; useful for low-income, uninsured, or underinsured patients.

Summary

The Lubiprostone access challenge in 2026 is real, but manageable with proactive prescribing strategies and the right patient-facing tools. Review our companion article on the Lubiprostone shortage: what providers need to know for more details on the supply situation and clinical alternatives.